Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Apr 13, 2018	Olerup QTYPE® Receives CE Mark Certification Fastest real time typing with Olerup QTYPE is now broadly available BRISBANE, Calif. , April 13, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Apr 10, 2018	CareDx Launches HeartCare® for Heart Transplant Recipients HeartCare combines AlloMap and AlloSure-Heart for Comprehensive Rejection Surveillance BRISBANE, Calif. , April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated,	View HTML
Toggle Summary Mar 29, 2018	CareDx Announces Completion of Debt Conversion Further Balance Sheet Simplification BRISBANE, Calif. , March 29, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,	View HTML
Toggle Summary Mar 22, 2018	CareDx Reports Fourth Quarter and FY2017 Financial Results 47 Transplantation Centers Offering AlloSure 9 Centers Enrolled in K-OAR BRISBANE, Calif. , March 22, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Mar 06, 2018	CareDx to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on March 22, 2018 BRISBANE, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML
Toggle Summary Mar 01, 2018	CareDx to Refinance Debt with Perceptive Advisors Balance Sheet to be Simplified with Single Term Loan BRISBANE, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary Feb 07, 2018	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif , Feb. 07, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag , Chief	View HTML CareDx to Participate in Upcoming Investor Conferences 22.5 KB
Toggle Summary Feb 05, 2018	CareDx Leadership in cfDNA Highlighted at CEoT CareDx symposium and panel presentations will showcase AlloSure experience	View HTML CareDx Leadership in cfDNA Highlighted at CEoT 25.2 KB
Toggle Summary Feb 01, 2018	First Patient Enrolled in AlloSure Registry Innovative AlloSure registry brings standardization to transplant centers	View HTML First Patient Enrolled in AlloSure Registry 19.7 KB
Toggle Summary Jan 16, 2018	TRIO Honors Peter Maag with Transplant Innovation Award Transplant Patient Organization Recognizes AlloSure's Impact	View HTML TRIO Honors Peter Maag with Transplant Innovation Award 19.3 KB